Keytruda Global Market Report 2025

Description

Keytruda, also known as pembrolizumab, is a monoclonal antibody medication utilized in cancer treatment. It falls under the category of immune checkpoint inhibitors, working by targeting and blocking the PD-1 (programmed cell death protein 1) protein in immune cells. This action assists the immune system in recognizing and attacking cancer cells effectively.

Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The keytruda market research report is one of a series of new reports from The Business Research Company that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The keytruda market size has grown strongly in recent years. It will grow from $21.6 billion in 2024 to $23.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to improved patient outcomes, increased adoption of immunotherapy, research and development, improved patient compliance, and increased adoption of keytruda.

The keytruda market size is expected to see strong growth in the next few years. It will grow to $33.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to expanding indications, emerging markets, increasing prevalence of cancer, rising healthcare expenditure, and growing demand for precision medicine. Major trends in the forecast period include demand for targeted therapies, advances in immunotherapy, advances in diagnostic technologies, demand for cancer treatment, and advances in cancer research.

The forecast of 9.2% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of PD-1 inhibitor therapies and companion diagnostic tests sourced from Ireland and Singapore, thereby delaying cancer immunotherapy regimens and elevating oncology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of cancer is expected to drive the growth of the Keytruda market in the coming years. Cancer is a complex set of diseases marked by the abnormal growth and spread of cells. Various factors, including genetics, lifestyle, environment, and hormones, contribute to the rising incidence of cancer. Keytruda (pembrolizumab) aids in cancer treatment by utilizing the body's immune system to more effectively combat cancer cells. It represents a major breakthrough in cancer therapy by empowering the immune system to target and destroy cancer cells, offering new hope for patients with advanced or metastatic cancers. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, reported that cancer cases had increased to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth rate of 2.19%. Therefore, the growing prevalence of cancer is driving the expansion of the Keytruda market.

Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.

In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

North America was the largest region in the keytruda market in 2024. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Keytruda Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on keytruda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for keytruda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The keytruda market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Cancer Type: Melanoma; Lung Cancer; Head And Neck Cancer; Hodgkin Lymphoma; Stomach Cancer; Urothelial Carcinoma
2) By Payer Type: Commercial; Medicare; Medicaid
3) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
Subsegments:
1) By Melanoma: Advanced Or Unresectable Melanoma; Adjuvant Treatment For Melanoma
2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Recurrent Or Metastatic Head And Neck Cancer
4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma; Relapsed Or Refractory Hodgkin Lymphoma
5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer; Esophagogastric Junction Cancer
6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma; Muscle-Invasive Bladder Cancer
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; Amgen Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Biogen Inc.; Chugai Pharmaceutical Co. Ltd.; BioNTech AG; Organon Co.; Ono Pharmaceutical Co. Ltd.; Samsung Bioepis Co. Ltd.; Fate Therapeutics Inc.; Merck Sharp & Dohme Corp.; KinBio; Schering-Plough AB; LGM Pharma LLC; Gritstone Bio Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r30536u

1. Executive Summary

2. Keytruda Market Characteristics

3. Keytruda Market Trends And Strategies

4. Keytruda Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Keytruda Growth Analysis And Strategic Analysis Framework

5.1. Global Keytruda PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Keytruda Market Growth Rate Analysis
5.4. Global Keytruda Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Keytruda Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Keytruda Total Addressable Market (TAM)

6. Keytruda Market Segmentation

6.1. Global Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Lung Cancer
Head And Neck Cancer
Hodgkin Lymphoma
Stomach Cancer
Urothelial Carcinoma
6.2. Global Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Commercial
Medicare
Medicaid
6.3. Global Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Specialty Pharmacies
6.4. Global Keytruda Market, Sub-Segmentation Of Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Advanced Or Unresectable Melanoma
Adjuvant Treatment For Melanoma
6.5. Global Keytruda Market, Sub-Segmentation Of Lung Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
6.6. Global Keytruda Market, Sub-Segmentation Of Head And Neck Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
Recurrent Or Metastatic Head And Neck Cancer
6.7. Global Keytruda Market, Sub-Segmentation Of Hodgkin Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Classical Hodgkin Lymphoma
Relapsed Or Refractory Hodgkin Lymphoma
6.8. Global Keytruda Market, Sub-Segmentation Of Stomach Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Advanced Or Metastatic Gastric Cancer
Esophagogastric Junction Cancer
6.9. Global Keytruda Market, Sub-Segmentation Of Urothelial Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Advanced Or Metastatic Urothelial Carcinoma
Muscle-Invasive Bladder Cancer

7. Keytruda Market Regional And Country Analysis

7.1. Global Keytruda Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Keytruda Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Keytruda Market

8.1. Asia-Pacific Keytruda Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Keytruda Market

9.1. China Keytruda Market Overview
9.2. China Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Keytruda Market

10.1. India Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Keytruda Market

11.1. Japan Keytruda Market Overview
11.2. Japan Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Keytruda Market

12.1. Australia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Keytruda Market

13.1. Indonesia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Keytruda Market

14.1. South Korea Keytruda Market Overview
14.2. South Korea Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Keytruda Market

15.1. Western Europe Keytruda Market Overview
15.2. Western Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Keytruda Market

16.1. UK Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Keytruda Market

17.1. Germany Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Keytruda Market

18.1. France Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Keytruda Market

19.1. Italy Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Keytruda Market

20.1. Spain Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Keytruda Market

21.1. Eastern Europe Keytruda Market Overview
21.2. Eastern Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Keytruda Market

22.1. Russia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Keytruda Market

23.1. North America Keytruda Market Overview
23.2. North America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Keytruda Market

24.1. USA Keytruda Market Overview
24.2. USA Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Keytruda Market

25.1. Canada Keytruda Market Overview
25.2. Canada Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Keytruda Market

26.1. South America Keytruda Market Overview
26.2. South America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Keytruda Market

27.1. Brazil Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Keytruda Market

28.1. Middle East Keytruda Market Overview
28.2. Middle East Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Keytruda Market

29.1. Africa Keytruda Market Overview
29.2. Africa Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Keytruda Market Competitive Landscape And Company Profiles

30.1. Keytruda Market Competitive Landscape
30.2. Keytruda Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Keytruda Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Novartis AG
31.3. AstraZeneca PLC
31.4. Bristol-Myers Squibb Company
31.5. Eli Lilly and Company
31.6. Amgen Inc.
31.7. Gilead Sciences Inc.
31.8. Teva Pharmaceutical Industries Ltd.
31.9. Biogen Inc.
31.10. Chugai Pharmaceutical Co. Ltd.
31.11. BioNTech AG
31.12. Organon Co.
31.13. Ono Pharmaceutical Co. Ltd.
31.14. Samsung Bioepis Co. Ltd.
31.15. Fate Therapeutics Inc.

32. Global Keytruda Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Keytruda Market

34. Recent Developments In The Keytruda Market

35. Keytruda Market High Potential Countries, Segments and Strategies

35.1 Keytruda Market In 2029 - Countries Offering Most New Opportunities
35.2 Keytruda Market In 2029 - Segments Offering Most New Opportunities
35.3 Keytruda Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer